5 Key Things to Know About This Leading Marijuana Stock's Future

You can count the number of pure-play marijuana stocks with a market cap of around $3 billion on one hand -- and have several fingers left over. GW Pharmaceuticals (NASDAQ: GWPH) ranks as one of the largest marijuana stocks on the market. But when the biotech reported its third-quarter results in August, investors were disappointed that the company was delaying its U.S. regulatory submission of cannabidiol (CBD) product Epidiolex. Over 10% of GW Pharma's market cap was wiped out in the days following the announcement.

Those concerns were a thing of the past when the company announced its fourth-quarter results on Monday. This time around, GW Pharmaceuticals' management team had nothing but good news to discuss. Here are five important things to know from their comments about the leading cannabinoid-focused biotech's future. (Quotes from S&P Global Market Intelligence.) 

Image source: Getty Images.

Continue reading

Source: Fool.com